C. dubliniensis has been identified as pathogen in Oropharyngeal
Candidiasis(OPC)particularly among HIV patients. Azole therapy is a cornerstone in OPC, but
resistance within C. dubliniensis isolates to diflucan is common.This is a prospective
collection of biological specimens from oropharyngeal cavity with the purpose of determining
the prevalence of C. dubliniensis in HIV/AIDS patients at the Duval County Department of
Health Comprehensive care Center. It is hereto proposed an estimation of azole-resistance in
This is a study to try to establish the prevalence of C. dubliniensis as a causative
organism of OPC in HIV and/or AIDS patients. We will aim to establish the resistance pattern
for azoles but also for Flucytosine and amphotericin of these isolates.
This study will serve as a support to previously published articles that have suggested
intrinsic azole-resistance within this particular species of candida and we will try to
postulate its possible correlation with clinical failure.
- Any patient 18 years old or older with a documented diagnosis of HIV infection with
or without AIDS-defining illnesses at the time of assessment, who is presenting with
clinical symptoms and physical findings compatible with oropharyngeal candidiasis (as
defined by the IDSA Guidelines for the Treatment and Management of HIV and HIV-
- Any prior diagnosis or established treatment for oropharyngeal, mucocutaneous or
esophageal candidiasis documented in the patient's chart or any proven diagnosis
based on reviews of physically available medical records and or history provided by
patients that can be subject to later confirmation pertaining to the use of
parenteral antifungals within 6 months prior to enrollment (azoles, echinocandins,
amphotericin B, Flucytosine, etc).